Why the study?
What are the cardiac risks and independent risk factors for adverse outcomes in patients with asymmetric septal hypertrophy undergoing noncardiac surgery?
What are the cardiac risks and independent risk factors for adverse outcomes in patients with asymmetric septal hypertrophy undergoing noncardiac surgery?
In patients with asymmetric septal hypertrophy, noncardiac surgery carries a high risk of reversible adverse cardiac events like heart failure, but irreversible morbidity and mortality are extremely low.
Reassures low irreversible cardiac risk despite frequent reversible events in asymmetric septal hypertrophy; leaves open prospective validation of major surgery as a modifiable factor.
Patients with asymmetric septal hypertrophy undergoing noncardiac surgery have a high incidence of adverse cardiac events, frequently manifested as congestive heart failure. However, irreversible cardiac morbidity and mortality was extremely low. Important independent risk factors for adverse outcome in all patients include major surgery and increasing duration of surgery.
No takes yet. Share an insight, caveat, or question.
Haering et al. (1996) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: